About us
Convert Pharmaceuticals, a preclinical and clinical-stage drug development company operating in Phase I-IIa&b, is dedicated to creating a proprietary drug pipeline that leverages tumor microenvironment-specific factors for therapeutic benefit.
Our flagship products are hypoxia activated prodrugs (HAPs). Hypoxia in tumors not only poses a therapeutic challenge by fostering resistance to conventional cancer treatments but also opens new avenues for targeted drug development limiting systemic toxicity. At Convert Pharmaceuticals, we integrate proprietary insights into the tumor microenvironment with our extensive expertise in drug and biomarker development. This integrated approach enables us to develop effective and well-tolerated HAPs tailored for precisely defined patient populations through advanced biomarker research.
Our team is bolstered by the profound expertise of Prof. Dr. Philippe Lambin, PhD in tumor hypoxia and cancer treatment, along with pioneering contributions from Assoc. Prof. Adam Patterson and Dr. Jeff Smaill of the Auckland Cancer Society Research Centre at the University of Auckland, New Zealand. Together, they drive our mission to overcome the challenges of tumor hypoxia and improve patient outcomes in cancer therapy.
Team
Philippe Lambin, M.D., Ph.D.
Chief Executive Officer
Philippe Lambin is a Clinician, Radiation Oncologist, “ERC advanced & twice ERC PoC grant laureate” respectively from 2016, 2017 & 2020 and pioneer in translational research with a focus on tumour hypoxia and Decision Support Systems. He has a PhD in Molecular Radiation Biology and is Professor at the University of Maastricht (Precision Medicine & Radiation Oncology) and at the University of Eindhoven (“Functional Imaging”, until 2011). He is co-author of more than 526 peer reviewed scientific papers (h-index 127 Google scholar), co-inventor of more than 20 patent families (filed or submitted) of which 10 are in the (pre)commercialization phase and (co) promoter of more than 60 completed PhD’s (2 with cum laude). Prof. P. Lambin also has extensive experience with clinical trials. He is one of the co-inventor of “Radiomics”, “Clinical Decision Support Systems”, “Distributed learning” from federated databases, genetically modified bacteria for cancer treatment, the combination of immunocytokines with radiation and Lymphocytes-Sparing Radiotherapy (LSRT).
Ludwig Dubois, Ph.D.
Chief Scientific Officer
The Chief Scientific Officer of our company is a doctor in Biomedical Sciences and an expert in pre-clinical studies concerning tumour hypoxia with more than 90 publications on this subject (h-index 52).
Jan Theys, Ph.D.
Chief Technology Officer
Jan, our Chief Technology Officer is a Doctor in Medical Sciences specialised in use of prokaryotic living medicine, tumour microenvironment and metabolism. He has >20 years of research experience with an extensive publication record in the field (h-index 41).
Anke Smets
Clinical Trial Manager
Anke has 17 years of experience in Clinical Research in large CROs and innovative SMEs. She has successfully led and managed multiple global clinical trials from start-up to close-out, ensuring quality, compliance, and efficiency throughout the process. She manages the operational coordination of Convert’s clinical trials.
Brice Van Eeckhout
Chief Operating Officer
With a strong background in Business Engineering and International Management and experience in building up and managing start-up, Brice is an entrepreneur in MedTech. He has the position of COO in Convert Pharmaceuticals.
Hélène Devroye
Clinical Development Manager
Hélène Devroye is an experienced Clinical Project Manager with knowledge in GCP and GMP, providing advice on the clinical development of the CP-506 Phase-1 trial. She implements best industry practices to ensure safety and well-being of the patients as well as quality and reliability of data.
Investors
Convert Pharmaceutical is privately held and backed by Wallonia (DG06) and the European Innovation Council (EIC Accelerator blended finance).